Dr. Giuseppe Del Priore reports

BRIACELL PARTNERS WITH NEW YORK CANCER & BLOOD SPECIALISTS (NYCBS) FOR PIVOTAL PHASE 3 STUDY OF BRIA-IMT(TM) IN ADVANCED BREAST CANCER

Briacell Therapeutics Corp. has partnered with New York Cancer & Blood Specialists (NYCBS), a group of leading community cancer centres in the United States, to evaluate the Bria-IMT combination with a checkpoint inhibitor in its pivotal phase 3 registration study in advanced breast cancer patients in New York.

"Cancer is complex. It takes a village to care for a cancer patient. At NYCBS, our mission is to offer cancer patients access to state-of-the-art treatments close to their homes, families and support networks, at convenient locations across Long Island, New York city and Upstate New York," stated Dr. Jeffrey Vacirca, chief executive officer of NYCBS. "We were impressed with the survival data of the Bria-IMT regimen to date and look forward to working with the Briacell team to make these novel therapeutics available to our patients."

"We are very honoured to work with the team of medical and health specialists at one of the nation's leading cancer centres," stated Dr. Giuseppe Del Priore, Briacell's chief medical officer. "Their insights and dedication to excellent patient care will be of utmost importance to us in our upcoming pivotal registration study."

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.